RECRUITING

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Official Title

A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors

Quick Facts

Study Start:2025-07-29
Study Completion:2029-04-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07115043

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participant ≥ 18 year
  2. * ECOG PS of 0 to 1
  3. * Provision of 'archival' tumor specimen
  4. * At least one measurable lesion according to RECIST v1.1,
  5. * Minimum life expectancy of 12 weeks
  6. * Adequate and stable cardiac function
  7. * Adequate bone marrow, liver and kidney function
  8. * Body weight ≥ 35 kg
  9. * Capable of giving signed informed consent
  1. * Any evidence of:
  2. * History or planned organ or allogeneic stem cell transplantation.
  3. * Active or prior documented autoimmune or inflammatory disorders, within the past 3 years
  4. * Any prior toxicities that led to permanent discontinuation of prior immunotherapy
  5. * Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anti-cancer therapy
  6. * Brain metastases unless treated, asymptomatic, stable, and not requiring continuous corticosteroids
  7. * Acute untreated or symptomatic malignant spinal cord compression, or a history of leptomeningeal carcinomatosis.
  8. * Active uncontrolled or chronic infection of hepatitis B, hepatitis C
  9. * Prior history of Grade ≥ 3 non-infectious pneumonitis.
  10. * Participant requires chronic immunosuppressive therapy (including steroids \> 10 mg prednisone/day or equivalent).
  11. * Receipt of live attenuated vaccine within 30 days.

Contacts and Locations

Study Contact

AstraZeneca Clinical Study Information Center
CONTACT
1-877-240-9479
information.center@astrazeneca.com

Study Locations (Sites)

Research Site
Grand Rapids, Michigan, 49546
United States
Research Site
Houston, Texas, 77030
United States
Research Site
San Antonio, Texas, 78229
United States

Collaborators and Investigators

Sponsor: AstraZeneca

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-29
Study Completion Date2029-04-09

Study Record Updates

Study Start Date2025-07-29
Study Completion Date2029-04-09

Terms related to this study

Additional Relevant MeSH Terms

  • Melanoma
  • Non-small Cell Lung Cancer
  • Squamous Cell Carcinoma (Skin)
  • Renal Cell Carcinoma
  • Merkel Cell Carcinoma
  • Triple Negative Breast Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Gastric Cancer/Gastroesophageal Junction Cancer
  • High Grade Serous Ovarian Carcinoma